Amphastar Pharmaceuticals, Inc.
AMPH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,798 | $2,985 | $1,360 | $1,113 |
| - Cash | $152 | $144 | $156 | $126 |
| + Debt | $651 | $624 | $103 | $105 |
| Enterprise Value | $2,297 | $3,465 | $1,307 | $1,091 |
| Revenue | $732 | $644 | $499 | $438 |
| % Growth | 13.6% | 29.1% | 14% | – |
| Gross Profit | $374 | $351 | $249 | $200 |
| % Margin | 51.1% | 54.5% | 49.9% | 45.6% |
| EBITDA | $277 | $240 | $146 | $112 |
| % Margin | 37.9% | 37.3% | 29.3% | 25.5% |
| Net Income | $160 | $138 | $91 | $62 |
| % Margin | 21.8% | 21.3% | 18.3% | 14.2% |
| EPS Diluted | 3.06 | 2.6 | 1.74 | 1.25 |
| % Growth | 17.7% | 49.4% | 39.2% | – |
| Operating Cash Flow | $213 | $184 | $89 | $98 |
| Capital Expenditures | -$41 | -$38 | -$24 | -$27 |
| Free Cash Flow | $172 | $145 | $65 | $71 |